ALS ONE, a Massachusetts-based nonprofit focused on accelerating research into amyotrophic lateral sclerosis (ALS), will soon become part of the ALS Network, an ALS advocacy organization that serves people with ALS in California and Hawaii. “This moment marks a real inflection point for the ALS community,” Sheri…
News
Elite athletes, military veterans, first responders, and other high performers have a significantly higher risk of developing amyotrophic lateral sclerosis (ALS) than the general population, and a new study aims to find out why. The initiative, Champion Insights, is seeking up to…
The first patient has been dosed in a Phase 1/2 clinical study of VTx-002, an experimental therapy being developed by VectorY Therapeutics for amyotrophic lateral sclerosis (ALS). The open-label PIONEER-ALS (NCT07287397) is enrolling up to 12 adults with ALS at sites in the U.S. and Europe. They will…
Origami Therapeutics is collaborating with Ipsen to develop experimental therapies designed to remove or correct abnormal proteins that build up in neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS). The partnership will focus on small molecules known as protein degraders and correctors. These compounds are designed to…
Coya Therapeutics has raised about $11.1 million in a private investment round to support commercial-readiness efforts for COYA 302, its experimental immune-modulating therapy being developed for amyotrophic lateral sclerosis (ALS). The funding was secured through the sale of more than 2.5 million company shares to two investors, the company…
A bipartisan team of U.S. lawmakers has reintroduced the ALS Better Care Act, a bill that aims to improve access to quality medical care for people with amyotrophic lateral sclerosis (ALS). The legislation was introduced in the House by Republican Brian Fitzpatrick of Pennsylvania and Democrats Jason Crow…
Patient enrollment has reached the halfway mark in an ongoing expanded access program (EAP) for MN‑166 (ibudilast), Medicinova’s oral anti-inflammatory drug for the treatment of amyotrophic lateral sclerosis (ALS). EAPs, also known as compassionate use programs, are designed to help people with serious or life-threatening diseases receive experimental…
In the U.S., clinical trials for amyotrophic lateral sclerosis (ALS) do not include enough non-white patients and women to fully represent the disease’s landscape in the real world, a study found. This lack of representation of certain groups may prevent researchers from generalizing clinical trial findings to the overall…
Scientists have developed a way to grow motor neurons, the highly specialized nerve cells that are lost in amyotrophic lateral sclerosis (ALS), opening the door to new research avenues for treatment discovery. The new approach directs rare adult brain progenitor cells to become corticospinal-like neurons, a type of nerve…
A viral infection can trigger a neurological disease similar to amyotrophic lateral sclerosis (ALS) in mice with a specific genetic profile, providing evidence for how genetics and environment may interact to cause the disorder, according to a new study. Findings suggest that while a virus may be…
Recent Posts
- A dream takes me back to a time before life with ALS
- ALS ONE joining ALS Network to strengthen research, services
- Rollator revamp needed because design matters for living well with ALS
- Study probes high ALS risk in elite athletes and other ‘champions’
- First ALS patient dosed in study of experimental gene therapy VTx-002